{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:25:23Z","timestamp":1787034323720,"version":"build-2736575974"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne) is a rare autosomal dominant autoinflammatory disorder caused by mutations in the PSTPIP1 gene. In pediatric patients, arthritis often precedes cutaneous manifestations by several years, leading to frequent misdiagnosis as septic arthritis. Treatment is challenging, with IL-1 inhibitors being the most pathophysiology-based first-line therapy, but their accessibility is limited by high costs. We reported an 11-year-old Chinese boy with a 7-year history of recurrent, migratory arthritis. Trio whole-exome sequencing identified a heterozygous PSTPIP1 c.770A&amp;gt;G (p.Glu257Gly) variant, classified as likely pathogenic. The father carried the same variant; he had experienced arthralgias in early childhood but became asymptomatic after age 10 without any treatment, demonstrating incomplete penetrance. This variant is extremely rare, reported in only one of 16 patients in the Eurofever registry, all of European descent, making this the first Asian case. Due to financial constraints, IL-1 inhibitors were inaccessible. Tofacitinib (3.5 mg twice daily, adjusted from adult dose based on body surface area) was initiated in February 2026. After 2 months, joint swelling and pain decreased significantly. As of July 10, 2026, no recurrence of joint swelling and pain had been observed during follow-up. However, radiography revealed irreversible structural damage (bone demineralization, joint space narrowing, osteophyte formation), and the patient still had limited mobility. Rehabilitation specialists advised against aggressive range-of-motion exercises and recommended home-based ultrasound and electrical stimulation to prevent muscle atrophy. Long-term follow-up is ongoing. PAPA syndrome should be considered in children with culture-negative, antibiotic-unresponsive recurrent arthritis, even without skin findings. Early genetic diagnosis can prevent unnecessary procedures. For patients who cannot access IL-1 inhibitors, tofacitinib may reduce inflammation, but it cannot reverse established joint damage. Given the relatively short follow-up duration, the long-term durability of response, safety, and impact of tofacitinib on disease progression remain to be determined. This report provides early, preliminary evidence of JAK inhibitor use in this population, contributing initial data to the limited Asian literature.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1870454","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:37:35Z","timestamp":1787031455000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A protracted diagnostic journey of pediatric PAPA syndrome and subsequent response to tofacitinib therapy: a case report and literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Shuien","family":"He","sequence":"first","affiliation":[{"name":"Department of Pediatrics, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine","place":["Guangzhou, China"]},{"name":"Xiaorong Luo\u2019s National Famous Expert Inheritance Studio, Guangdong Provincial Hospital of Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Deng","sequence":"additional","affiliation":[{"name":"Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine","place":["Guangzhou, China"]},{"name":"Ying Lv\u2019s Expert Inheritance Studio, Guangdong Provincial Hospital of Chinese Medicine","place":["Guangzhou, China"]},{"name":"Youjia Xu\u2019s Famous Expert Inheritance Studio, Guangdong Provincial Hospital of Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine","place":["Guangzhou, China"]},{"name":"Mingzhao Du\u2019s Inheritance Studio of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)63565-9","article-title":"A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome","volume":"72","author":"Lindor","year":"1997","journal-title":"Mayo Clin Proc"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0265-1","article-title":"PAPA, PASH and PAPASH syndromes: Pathophysiology, presentation and treatment","volume":"18","author":"Cugno","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/11.8.961","article-title":"Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder","volume":"11","author":"Wise","year":"2002","journal-title":"Hum Mol Genet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00247-018-4246-1","article-title":"Imaging findings of sterile pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) syndrome: differential diagnosis and review of the literature","volume":"49","author":"Martinez-Rios","year":"2019","journal-title":"Pediatr Radiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X20918988","article-title":"A child with recurrent pyogenic arthritis with the PSTPIP1 mutation","volume":"8","author":"Guo","year":"2020","journal-title":"SAGE Open Med Case R"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.08.028","article-title":"Phenotypic associations of PSTPIP1 sequence variants in PSTPIP1-associated autoinflammatory diseases","volume":"141","author":"Boursier","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00018-022-04173-w","article-title":"PSTPIP1-LYP phosphatase interaction: structural basis and implications for autoinflammatory disorders","volume":"79","author":"Manso","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/art.34332","article-title":"Brief report: genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne)","volume":"64","author":"Demidowich","year":"2012","journal-title":"Arthritis Rheumatism"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-11-S1-A149","article-title":"PW02-009 - PAPA syndrome: results from the Euroefever registry","volume":"11","author":"Caorsi","year":"2013","journal-title":"Pediatr Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"20\u20139","DOI":"10.18502\/igj.v5i1.14066","article-title":"Pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) and PAPA-like syndromes: Systematic review of the literature","volume":"5","author":"Hajialigol","year":"2022","journal-title":"Immunol Genet J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1055\/s-0044-1790238","article-title":"Chronic noninfectious osteomyelitis: A review of imaging findings","volume":"35","author":"Chandola","year":"2024","journal-title":"Indian J Radiol Imaging"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-025-01250-9","article-title":"The pathogenesis, clinical presentations and treatment of monogenic systemic vasculitis","volume":"21","author":"G\u00fcl","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.04.016","article-title":"Single amino acid charge switch defines clinically distinct proline-serine-threonine phosphatase-interacting protein 1 (PSTPIP1)-associated inflammatory diseases","volume":"136","author":"Holzinger","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225085","article-title":"Interrupting an IFN-\u03b3-dependent feedback loop in the syndrome of pyogenic arthritis with pyoderma gangrenosum and acne","volume":"83","author":"Lee","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1339337","article-title":"Efficacy and safety of anakinra and canakinumab in PSTPIP1-associated inflammatory diseases: a comprehensive scoping review","volume":"14","author":"Sanz-Cabanillas","year":"2024","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201268","article-title":"Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review","volume":"72","author":"Ter Haar","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.12.816","article-title":"Biologics and JAK inhibitors for the treatment of monogenic systemic autoinflammatory diseases in children","volume":"151","author":"Du","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.ard.2026.01.007","article-title":"Safety of multitargeted therapy using 2 biologics or 1 biologic and 1 JAKi in refractory paediatric inflammatory disorders: a retrospective multicentric cohort","volume":"85","author":"Triaille","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.735851","article-title":"Case report: Pyogenic arthritis, pyoderma gangrenosum, and acne: A single-center experience and literature review","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112140-20200430-00456","article-title":"Targeted therapy of pyogenic sterile arthritis, pyoderma gangrenosum, and acne syndrome (PAPA): a case report and literature review","volume":"58","author":"Liang","year":"2020","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2004.08.001","article-title":"Abnormal production of tumor necrosis factor (TNF) -- alpha and clinical efficacy of the TNF inhibitor etanercept in a patient with PAPA syndrome [corrected","volume":"145","author":"Cortis","year":"2004","journal-title":"J Pediatr"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh479","article-title":"Anakinra for flares of pyogenic arthritis in PAPA syndrome","volume":"44","author":"Dierselhuis","year":"2005","journal-title":"Rheumatol (Oxford England)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09404.x","article-title":"Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra","volume":"161","author":"Brenner","year":"2009","journal-title":"Br J Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3181e969b9","article-title":"Clinical efficacy of etanercept for treatment of PAPA syndrome","volume":"16","author":"Shaver","year":"2010","journal-title":"JCR"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.126185","article-title":"Variable expression and treatment of PAPA syndrome","volume":"70","author":"Schellevis","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140060","article-title":"Osteolytic lesion in PAPA syndrome responding to anti-interleukin 1 treatment","volume":"41","author":"Caorsi","year":"2014","journal-title":"J Rheumatol"},{"key":"B28","article-title":"A novel de novo PSTPIP1 mutation in a boy with pyogenic arthritis, pyoderma gangrenosum, acne (PAPA) syndrome","volume":"32","author":"Fathalla","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s15010-017-0996-1","article-title":"Pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA) syndrome: differential diagnosis of septic arthritis by regular detection of exceedingly high synovial cell counts","volume":"45","author":"L Ffler","year":"2017","journal-title":"Infection"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1870454\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:37:37Z","timestamp":1787031457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1870454\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2026.1870454"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1870454","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"article-number":"1870454"}}